Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jan 2018
Randomized Controlled Trial Multicenter Study Comparative StudyAdalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point. ⋯ After 26 weeks of adalimumab treatment, significant improvements were seen in the primary and all ranked secondary end points and in signs and symptoms of moderate-to-severe nail psoriasis versus with placebo and no new safety risks were identified.
-
J. Am. Acad. Dermatol. · Jan 2018
Comparative StudyAntimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remains debated. ⋯ With the exception of retinopathy, which was not seen with Q, the risks for other toxicities associated with Q monotherapy or combination treatment were not significantly different from those with HCQ.